Daniel: from MD Anderson to Shanghai for ivonescimab, through an ICU scare to stability

Patient from

United States

Daniel

In his 70s, United States; also living with Parkinson’s disease

Condition

Advanced non-small cell lung cancer, with Parkinson’s disease

Treatment

Ivonescimab (PD-1/VEGF bispecific antibody) with multidisciplinary care

Hospital

Jiahui International Cancer Center (Shanghai Jiahui International Hospital)

City

Shanghai

Before China

Daniel had exhausted the standard lines of treatment at MD Anderson Cancer Center in the United States. His doctors recommended ivonescimab, the first approved PD-1/VEGF bispecific antibody for solid tumours, which was available only in China at the time.

Getting care in China

After a video consultation in late November, scheduled within a week of the family’s first inquiry, they chose Jiahui International Cancer Center in Shanghai for its multidisciplinary expertise and U.S.-trained oncology chief Dr Xuan Linli. The hospital is partnered with Massachusetts General Hospital Cancer Center and offers remote consultations, travel coordination and ongoing family updates.

Timeline

1. 1November 2025His doctors recommend ivonescimab after standard options are exhausted.
2. 2November 2025Video consultation with Jiahui, within a week of the first inquiry.
3. 3In Shanghai: ivonescimab treatment; immune-related complications managed in the ICU.
4. 4March 2026Condition stabilised; hospital press release published on 7 March 2026.

Outcome

During treatment he developed immune-related complications that needed ICU care. Oncology, neurology and critical-care teams worked together, with input from ivonescimab principal investigator Dr Zhou Caicun. His condition then stabilised, and care continues to focus on disease control. Stable disease is not a cure.

Each story is one person’s reported experience, not a promise of results. Outcomes differ with diagnosis and the individual. This is not medical advice; treatment decisions are made with the treating hospital.